title: Marshaling the immune system to eliminate minimal residual disease in B-ALL.
authors.forename: Karyn
authors.initials: K
authors.lastname: Hede
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D018941:Antigens, CD19 / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D000080045:Inotuzumab Ozogamicin; D008213:Lymphocyte Activation; D015337:Multicenter Studies as Topic; D018365:Neoplasm, Residual / Q000276:immunology / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000187:drug effects / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D012074:Remission Induction; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D033581:Stem Cell Transplantation
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018941:Antigens, CD19; D000951:Antigens, Neoplasm; C497867:CD22 protein, human; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D051918:Sialic Acid Binding Ig-like Lectin 2; D000080045:Inotuzumab Ozogamicin